| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46276 | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Oct, 2024
(1 year, 1 month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE46276 (Pediatric) | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Apr, 2025
(1 year, 7 months from now) | |
| US8425934 | ASTRAZENECA | Pharmaceutical compositions |
Apr, 2030
(6 years from now) | |
|
US8425934 (Pediatric) | ASTRAZENECA | Pharmaceutical compositions |
Oct, 2030
(7 years from now) | |
| US10300065 | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jan, 2036
(12 years from now) | |
|
US10300065 (Pediatric) | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jul, 2036
(12 years from now) | |
Brilinta is owned by Astrazeneca.
Brilinta contains Ticagrelor.
Brilinta has a total of 6 drug patents out of which 0 drug patents have expired.
Brilinta was authorised for market use on 20 July, 2011.
Brilinta is available in tablet;oral dosage forms.
Brilinta can be used as treatment of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction; reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with a history of myocardial infarction; treatment of stroke in patients with acute coronary syndrome or a history of myocardial infarction; treatment of myocardial infarction in patients with acute coronary syndrome or a history of myocardial infarction; reduction of the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack; treatment of myocardial infarction or stroke in patients with coronary artery disease at high risk for such events; reduction of the rate of a first myocardial infarction or stroke in patients with coronary artery disease at high risk for such events, reducing the rate of cardiovascular death, myocardial infarction (mi), and stroke in a patient receiving 75-100 mg aspirin daily with a history of mi by administering 60 mg ticagrelor twice daily; reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspirin daily and having or who had acute coronary syndrome by administering 60 mg ticagrelor twice daily.
The generics of Brilinta are possible to be released after 27 July, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | Nov 5, 2023 |
| M (M) | May 9, 2025 |
| Pediatric Exclusivity (PED) | Nov 9, 2025 |
Drugs and Companies using TICAGRELOR ingredient
Market Authorisation Date: 20 July, 2011
Treatment: Reducing the rate of cardiovascular death, myocardial infarction (mi), and stroke in a patient receiving 75-100 mg aspirin daily with a history of mi by administering 60 mg ticagrelor twice daily; Red...
Dosage: TABLET;ORAL
BRILINTA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic